Navigation Links
Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Date:12/13/2007

RALEIGH, N.C., Dec. 13 /PRNewswire/ -- The most recent study from the landmark Framingham trial demonstrates the clinical significance of knowing the number of LDL particles (LDL-P) by NMR in the management of a patient's risk for heart disease. This longitudinal outcomes study shows that low levels of LDL particles are associated with fewer cardiovascular disease (CVD) related events than equivalently low levels of LDL cholesterol. The findings confirm that low levels of LDL cholesterol may have limitations and suggests that managing patients to LDL-P targets of therapy may improve patient outcomes.

The NMR LipoProfile test, developed by LipoScience, Inc., is the only test that quantifies the number of LDL particles (LDL-P). LDL particle information is used by clinicians to better manage a patient's cardiovascular health by lowering the number of LDL particles (LDL-P) to acceptable levels using familiar LDL lowering therapies.

Authors, William C. Cromwell, MD, et al, compared the relative ability of LDL cholesterol (LDL-C) and the number of LDL particles (LDL-P), two alternative measures of LDL, to predict cardiovascular disease events at low levels. The study found low numbers of LDL particles, as measured by the NMR LipoProfile test, to be associated with 27% fewer cardiovascular disease events than equivalently low levels of LDL cholesterol. This suggests a clinical role for LDL-P as a treatment target for LDL management.

The authors concluded that because the cholesterol content of LDL particles between individuals is highly variable, LDL cholesterol levels often underestimate the number of LDL particles and a patient's risk for heart disease. In fact, data from another Framingham population showed that 50% of individuals who suffered a heart attack had normal LDL cholesterol levels. Many patients who are being managed to LDL-C targets of therapy, as established by current guidelines, are still at significant risk for cardiovascular disease (CVD). In this study, LDL-P was shown to be a more sensitive indicator of low CVD risk than LDL-C or non-HDL-C, another potential treatment target. The study reinforces the limitations of LDL cholesterol and the importance of managing patients to acceptably low levels of LDL-P to avoid CVD related events such as heart attack.

Data in over 100 published papers reinforce the superior clinical value of the NMR LipoProfile test. These most recent findings were published in the National Lipid Association's December issue of Journal of Clinical Lipidology.

(1) William C. Cromwell, MD, James D. Otvos, PhD et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidology 2007; 1: 583-592.


'/>"/>
SOURCE LipoScience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Sports Legacy Institute Announces Findings of Forensic Examinations on Wrestler Chris Benoits Brain
5. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
6. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Top Washington Health Officials to Honor Framingham Heart Study Participants
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):